Contraindicated (1)bortezomib will enhance the level or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or reasonable CYP2C19 inhibitors may well increase mavacamten systemic exposure, resulting in coronary heart failure as a result of systolic dysfunction. This medication is applied to deal with selected sorts of cancer https://finnhvgsf.blog-a-story.com/6469459/5-easy-facts-about-thromboxane-b2-described